Hepatitis E: a complex and global disease

E Pelosi1 and I Clarke2

1Department of Microbiology and Virology, Health Protection Agency, Southeast Regional Laboratory, Southampton General Hospital, Southampton, UK; and 2Department of Molecular Microbiology, Southampton Medical School, Southampton General Hospital, Southampton, UK.

Correspondence
Dr E Pelosi, Department of Microbiology and Virology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO1 6YD, UK.
E-mail: Emanuela.Pelosi@suht.swest.nhs.uk

Thirty years after its discovery, the hepatitis E virus (HEV) continues to represent a major public health problem in developing countries. In developed countries, it has emerged as a significant cause of non-travel-associated acute hepatitis. HEV infects a wide range of mammalian species and a key reservoir worldwide appears to be swine. Genomic sequence similarity between some human HEV genotypes and swine HEV strains has been identified and we know that humans can acquire HEV infection from animals. Although for the most part the clinical course of HEV infection is asymptomatic or mild, significant risk of serious disease exists in pregnant women and those with chronic liver disease. In addition, there are data on the threat of chronic infections in immunocompromised patients. Beyond management of exposure by public health measures, recent data support that active immunisation can prevent hepatitis E, highlighting the need for vaccination programmes. Here we review the current knowledge on HEV, its epidemiology, and the management and prevention of human disease.

Introduction
First recognised in Asia almost 30 years ago as the main cause of non-A, non-B enterically transmitted hepatitis,1,2 hepatitis E virus (HEV) is now acknowledged to have worldwide distribution.

In countries with poor sanitation, HEV is endemic and typically causes explosive outbreaks of acute hepatitis, usually associated with faecal contamination of the water supply. The disease is generally mild, yet pregnant women suffer significant morbidity and mortality.3–5

In contrast, in countries with high standards of sanitation, hepatitis E occurs sporadically, initially identified as an imported disease in travellers from highly endemic regions, but subsequently diagnosed in patients with no travel history as well; this latter form has been named ‘hepatitis E indigenous to developed countries’.6–26

Phylogenetic analysis of HEV genome from different isolates has led to the identification of four main genotypes, with genotypes 1 and 2 circulating in Africa and Asia, genotype 3 showing a broad distribution worldwide, and genotype 4 being restricted to Asia.

Genotypes 3 and 4 are enzootic in a variety of wild and domestic animals, particularly pigs,8,27–36 which gave rise to the question of whether human HEV infection is a zoonosis? Evidence from Japan37–40 and China28 now confirms that humans can acquire HEV infection from animals.

Hepatitis E represents a significant public health and economic burden particularly in countries where the absence of sanitation infrastructures, or their breakdown as a consequence of wars or natural disasters, brings the hygienic conditions below a safe level.4,41,42 The development of an effective vaccine is expected to dramatically reduce the incidence of the disease, particularly in the most susceptible individuals such as pregnant women.

Virology
Taxonomy and virus structure
In the early 1980s, the observation that individuals involved in epidemics of jaundice were seronegative for markers of acute hepatitis A and B suggested the existence of an unrecognised aetiological agent of enterically transmitted hepatitis.1,2 The confirmation came in 1983, when small, virus-like particles were identified by immune electron microscopy in stool specimens from a volunteer experimentally infected with pooled faecal extracts from human cases of epidemic non-A, non-B hepatitis.43 The pathogen, HEV, is a non-enveloped virus, 27–30 nm in diameter, with an icosahedral capsid. In the early 1990s, the virus genome was cloned44,45 and diagnostic antibody assays were developed.46 After being provisionally assigned to the Caliciviridae family,47 HEV was re-classified as the sole member of the genus Hepevirus, family Hepeviridae, in 2004.48
Genomic organisation and viral proteins

The HEV genome consists of a single-stranded RNA molecule with positive polarity approximately 7300 nucleotides in length. It comprises a short 5’ noncoding region (28 nucleotides), followed by three open reading frames (ORF), a 3’ noncoding region (65–74 nucleotides), and a poly(A) tail (Figure 1). The genome is capped at its 5’ terminus and capping is required for virus viability.

ORF1 (approximately 5 kb) encodes a large nonstructural polyprotein with key functions for viral genome replication and viral protein processing. ORF2 (approximately 2 kb) occupies the 3’ end of the coding region and encodes the capsid protein. The N-terminal region of ORF2 protein binds the 5’ noncoding region of the HEV genome and is possibly involved in viral encapsidation. Only the ORF2 recombinant protein truncated at its N-termini can efficiently self-assemble in vitro into empty, virus-like particles. These share antigenic properties with the native HEV capsid protein, although they are smaller than the native virions.

ORF3 is a small reading frame (372 bases) with the 5’ end overlapping ORF1 by four nucleotides and the 3’ end overlapping ORF2 by 331 nucleotides; it encodes a small phosphoprotein that associates with the cytoskeleton and the capsid protein. The product of ORF3 is possibly involved in modulation of cell signalling and in the assembly of the HEV nucleocapsid; recently, it has been shown that this protein is essential for infectivity in vivo but not in vitro. The poly(A) tail is necessary for binding of RNA-dependent RNA polymerase (RdRp) to the 3’ noncoding region.

Compared with genotypes 1–3, the genome of genotype 4 contains a nucleotide insertion (U) just after the second AUG codon of ORF3, which changes the downstream reading frames so that, for genotype 4, different AUG codons were initially expected to initiate translation in both ORF2 and ORF3. However, a recent study by Graff et al. using a replicon, demonstrated that ORF2 and ORF3 proteins are produced from a single subgenomic RNA of approximately 2.2 kb, which initiates downstream of the first two AUG codons of ORF3 in genotypes 1–3 (downstream of the insertion of U in genotype 4), using two closely spaced start codons. It is therefore expected that both ORF2 and ORF3 proteins are similar in size in all four genotypes.

Resistance to physical and chemical agents

Boiling and chlorination of water represent the main measures to control and prevent infection. However, Emerson et al. reported that HEV is moderately resistant to heat inactivation. This finding was further corroborated in a more recent study that showed how HEV was still infectious on incubation at 56°C for 30 min.

HEV genetic diversity

Comparative nucleotide sequence analysis of whole genomes of HEV isolates has revealed extensive genomic diversity leading to the identification of four major genotypes and several subtypes within each genotype (Figure 2). However, although the separation of HEV into four major genogroups is widely accepted, so far there is no agreement about the number of subtypes within each genotype. Genomic regions that have been used for phylogenetic purposes include a 301-nucleotide-long sequence at the 5’ end of the ORF2 region and a 306-nucleotide-long sequence in the RdRp of ORF1.

Replication in cell culture

The lack of efficient cell culture systems has hampered detailed studies on HEV biology, critical for helping to develop diagnostic assays and vaccine research. Replication and propagation of HEV was attempted with limited success by using continuous cell lines and primary hepatocytes from nonhuman primates. Recently, more efficient cell-culture systems were developed in cell lines, allowing studies on HEV thermal stability and improving neutralisation tests. It was shown that anti-HEV antibodies are broadly crossreactive because HEV genotype 3 was neutralised by convalescent serum samples from patients.

![Figure 1](image-url) Schematic organisation of genomic and subgenomic HEV RNAs. ORF1 encodes a nonstructural polyprotein; ORF2 encodes the capsid protein; ORF3 encodes a phosphoprotein. Met, methyltransferase; Y, no function assigned at present; Pr, putative papain-like cysteine protease; P, proline ‘hinge’; X, no function assigned at present; Hel, RNA helicase; RdRp, RNA-dependent RNA polymerase.
infected with HEV genotypes 1, 3, and 4. Similarly, genotype 1 was neutralised by convalescent serum samples obtained from rhesus monkey infected with any of the four mammalian genotypes. In addition, serum specimens obtained 24 years after the onset of HEV infection could prevent the propagation of HEV in cell culture, suggesting that long-lasting HEV antibodies with neutralisation activity are induced.

Epidemiology
Geographical distribution of HEV according to genotype
The geographical distribution of HEV genotypes is complex and continuously evolving (Figure 3). Genotype 1 extensively circulates in Asia (including India, Pakistan, Nepal, Bangladesh, China, Kyrgyzstan, and Uzbekistan) and Africa (including Egypt, Algeria, Morocco, Namibia, Sudan, and Chad), whereas genotype 2 has been isolated only in Mexico and some African countries (Nigeria, Namibia, Chad, and Sudan). Genotype 3 has been detected worldwide (America, Europe, Asia, Australia, and New Zealand) with the exception of Africa, whereas genotype 4 is restricted to India and East Asia. Although genotypes 1 and 2 are considered human viruses, genotypes 3 and 4 have been isolated from both humans and animals. Of significant interest is the unique distribution of HEV isolates in India, as human and swine HEVs belong to different genotypes (genotype 1 and genotype 4, respectively); genotype 4 appears to be specifically restricted to swine and it has never been isolated from humans, in spite of extensive investigations. Phylogenetic analysis shows that the Indian HEV genotype 4 represents a distinct variant among HEV genotype 4 isolates with 26 unique amino-acid substitutions (16 in ORF1, 8 in ORF2, and 2 in ORF3). Whether the difference in sequence, particularly in ORF2, determines tropism and explains the lack of infectivity in humans remains to be determined.

Mode of transmission
Waterborne
In developing countries, HEV is transmitted through the faecal–oral route, mainly by the consumption of water contaminated with sewage disposal. In developed countries, HEV RNA has been detected in human sewage only occasionally. Interestingly, HEV rescued from sewage in Spain was infectious for rhesus monkey, raising the possibility that HEV might occasionally...
contaminate the environment and shellfish even in non-epidemic regions.\textsuperscript{16,131,132}

**Foodborne**

Evidence that food can transmit HEV came from Japan, where acute hepatitis E was diagnosed in patients who consumed raw or undercooked pig liver and intestine,\textsuperscript{23} wild boar meat and liver,\textsuperscript{38,110,133} and deer meat\textsuperscript{40} contaminated with the virus. HEV with identical nucleotide sequence was detected both in the blood of affected patients and in batches of meat and liver not consumed.\textsuperscript{40,109,133} A higher HEV IgG seroprevalence in Japanese individuals with frequent dietary consumption of raw deer meat, in comparison with a control group, indirectly supports the foodborne route.\textsuperscript{134} Food as a vehicle of infection has not yet been proven in other developed countries.

**Person-to-person transmission**

In contrast to hepatitis A virus (HAV) infection, secondary transmission among household members of patients with acute hepatitis E is an uncommon event,\textsuperscript{135,136} both in the context of outbreaks\textsuperscript{137} and sporadic infections.\textsuperscript{138,139}

**Parenteral transmission**

HEV-infected individuals can transmit the infection by donating blood during the viraemic period. Viraemia can be detected even in asymptomatic infections and during the incubation period,\textsuperscript{140,141} even in the absence of aminotransferase elevation.\textsuperscript{140} Transmission of HEV via blood transfusion has been documented in several countries, including Saudi Arabia,\textsuperscript{142} Japan,\textsuperscript{105,143,144} and the UK,\textsuperscript{145} where matching RNA sequences were found in blood donors and their recipients.

**Mother-to-child transmission**

Mother-to-child transmission of HEV has been scarcely documented; however, the available data suggest a significant rate of HEV vertical transmission among the HEV RNA-positive mothers with worsening liver disease.\textsuperscript{146-149}

**Epidemic versus sporadic forms and seasonality**

In the developing world, HEV infection represents the most common aetiological agent of periodic outbreaks of acute hepatitis.\textsuperscript{42,130,136,130} Epidemics are most frequent during the monsoon season when flooding causes faecal contamination
of drinking water.\textsuperscript{41} Between epidemics, HEV is transmitted in a discrete manner leading to the onset of sporadic forms of acute hepatitis. In India, 30–70\% of all cases of acute sporadic hepatitis are caused by HEV infection.\textsuperscript{41,151}

In economically developed regions, indigenous hepatitis E is largely a sporadic disease. However, in Japan, small outbreaks have been described as a consequence of consumption of the same contaminated food.\textsuperscript{152,153} A small outbreak involving a family with two children has also been reported in France.\textsuperscript{139} No clear seasonality has been observed in developed countries.\textsuperscript{24,154}

Age- and sex-specific clinical attack rates and case fatality rates

Clinical infection concentrates among adolescents and young adults in countries of high endemicity. During outbreaks, the clinical attack rate (3–30\%)\textsuperscript{136,150,155–157} is highest among pregnant women.\textsuperscript{4,158,159} The mortality rate, which is usually low (0.07–0.6\%),\textsuperscript{136,150,160,161} can reach values as high as 25–31\% in pregnant women, particularly during the third trimester of pregnancy.\textsuperscript{4,136,150,155,162–164}

A distinct characteristic of hepatitis E indigenous to developed countries is its high attack rate among older male adults.\textsuperscript{13,26,100} This has been observed in both Europe\textsuperscript{10,16,18,20,100,101} and Japan,\textsuperscript{24} which experienced the greatest number of detected cases. No documented case of hepatitis E has been identified in pregnant women in this different epidemiological setting.

A high mortality, ranging between 25 and 70\%, has been recently documented among patients already suffering from chronic liver disease of different aetiologies. These observations were made both in highly endemic countries, such as India,\textsuperscript{165–168} Pakistan,\textsuperscript{169} and Nepal,\textsuperscript{170} where hepatitis E is caused by genotype 1, and in Europe,\textsuperscript{171} where indigenous hepatitis E is linked to genotype 3.

Seroprevalence of HEV infection

HEV seroprevalence studies have been conducted using several antibody assays based on different recombinant antigens, which do not always include the most relevant B-cell epitopes, leading to lack of sensitivity and poor reciprocal concordance.\textsuperscript{172} In particular, a greater sensitivity of currently available antibody assays has been reported in detecting overt disease in comparison with subclinical infections,\textsuperscript{173} which may hamper seroepidemiological investigations. Antibody assays based on the ORF2 protein, which exposes at least one major crossreactive epitope shared by all HEV genotypes,\textsuperscript{56,62,174} should be used for investigating seroepidemiology\textsuperscript{46,56,175,176} (see ‘Diagnosis’).

Seroepidemiology studies in HEV epidemic countries, such as India, have revealed that HEV infection is rare in children, reaching peak prevalence (33–40\%) only in early adulthood.\textsuperscript{177} These data are in striking contrast with HAV serosurveys, showing anti-HAV antibodies in the majority of children by the age of three years.\textsuperscript{177} The reason for the difference in age-specific seroprevalence between HAV and HEV, both transmitted by the faecal–oral route, remains unanswered.

In contrast, HEV seroepidemiology closely mirrors that of HAV in Egypt, a country highly endemic for HEV infection (similar to India), where anti-HEV antibodies are detectable in 65\% of children younger than 10 years.\textsuperscript{178} Although the reason for the earlier exposure in life in Egypt remains unknown, the widespread immunity of the population at an early age might account for the absence of large outbreaks of hepatitis E in the general population\textsuperscript{179} and among pregnant women.\textsuperscript{180}

In rural southern China, where the majority of HEV infections are zoonotic (genotype 4), anti-HEV IgG is rarely detected in children, rapidly increases in young adults, and peaks (60–80\%) at the age of 60 years.\textsuperscript{181} Interestingly, after 30 years of age, but not in younger age groups, the seroprevalence is two times higher for men than for women, suggesting a link with different social roles adopted by men and women once families are established.\textsuperscript{181}

Seroepidemiology investigations in developed regions have revealed the ubiquitous presence of anti-HEV antibodies in the analysed populations, although with significant differences between and within countries.\textsuperscript{11,172,182–186} A significant concern is the high seroprevalence among US blood donors (18–21\%)\textsuperscript{184,185} compared with individuals professionally exposed to swine HEV, such as veterinarians (23–26\%).\textsuperscript{184}

Some studies have documented an increasing seroprevalence with age in both sexes, suggesting a continuous ongoing exposure to HEV.\textsuperscript{172,182,187,188} In Japan, age-specific profiles of anti-HEV and anti-HAV antibodies suggest silent HEV infection in the last few decades, during which HAV infection rates declined.\textsuperscript{188}

Zoonosis and host range

The possibility that HEV infection can be a zoonosis was raised when a virus, closely related to the HEV human strains, was isolated from pigs, initially in the USA\textsuperscript{189} and, subsequently, worldwide.\textsuperscript{28,32–36,96,112,183,190–193}

Experimental cross-species infections between swine and primates have shown that swine HEV could infect primates (surrogates for human infection), and the US-2 strain of human HEV (genotype 3) could infect specific pathogen-free pigs.\textsuperscript{194} In contrast, US pigs could not support replication of human epidemic strains (genotypes 1 and 2).\textsuperscript{195} Similarly, Indian pigs could be infected with swine HEV (genotype 4) but not with human HEV (genotype 1).\textsuperscript{112}

These findings are supported by phylogenetic analysis data showing a high degree of nucleotide and amino-acid sequence homology between swine and human HEV isolates of genotypes 3 and 4 from the same geographical regions, suggesting that pigs may act as a reservoir for human infection.\textsuperscript{29,55,109,115,116,125} On the contrary, swine HEV strains are highly divergent from the human strains of HEV classified within genotypes 1 and 2.\textsuperscript{69}
Pigs are infected via the faecal–oral route\textsuperscript{196} and develop a self-limiting subclinical infection\textsuperscript{199,197,198} with transient viraemia (one to two weeks) but prolonged viral shedding (three to four weeks) in faeces. Current pig-raising practices perpetuate exposure of pigs to their waste, promoting viral transmission.\textsuperscript{38}

Seroprevalence studies in pigs have shown the presence of HEV IgG in an unexpectedly high proportion of animals,\textsuperscript{36,199–201} with peaks up to 85% in the UK,\textsuperscript{14} 95–98% in India,\textsuperscript{127} and 70–100% in Japan.\textsuperscript{109,202,203} Although pigs are infected primarily at the early stage of production (1–3 months), HEV can still be detected by PCR at slaughter age, meaning that swine HEV can enter the food chain.\textsuperscript{28,36,98} This has been shown in Japan, where infectious HEV was found in 2% of the pig liver packages ready for sale,\textsuperscript{39} and more recently in the USA\textsuperscript{30} and in The Netherlands.\textsuperscript{204} HEV RNA was also detected in 3.1% of bile samples from swine in abattoirs in eastern China.\textsuperscript{28}

HEV replicates in different visceral organs,\textsuperscript{192,205,206} This explains the common foodborne transmission in Japan owing to the gastronomic habit of eating rarely, or poorly cooked, pig liver and intestines. Despite absence of evidence for HEV replication in muscles, HEV infection has been transmitted by consumption of meat from boar and deer as well.\textsuperscript{38,40,113}

The finding of infectious HEV in pig-farm manure slurry samples\textsuperscript{193} suggests that human exposure to swine waste may represent an alternative mode of transmission of zoonotic strains, particularly in regions where the water supply comes from wells, rivers, and streams, and where sewage treatment is not generally available.\textsuperscript{181} In rural eastern China, where 9.6% of pig herds were found to be HEV RNA-positive by stool samples, a 74% higher risk of infection among people professionally engaged in swine farming was observed. Seroprevalence increased with the duration of occupational exposure to swine.\textsuperscript{28} There was also a 29% higher risk of infection in people without occupational exposure to swine and residing in communities downstream of the Chinese swine farms, compared with those living in communities upstream.\textsuperscript{28} Compared with control individuals, increased HEV IgG seroprevalence was also detected in people with occupational exposure to pigs in other countries, including Sweden and The Netherlands.\textsuperscript{183,207}

Seroprevalence studies have shown that HEV natural infection is widespread in many species of wild and domestic mammals, including rats,\textsuperscript{208–212} cattle,\textsuperscript{115,209} goats,\textsuperscript{127} wild mongooses,\textsuperscript{215} monkeys,\textsuperscript{214} dogs,\textsuperscript{215} and pet cats,\textsuperscript{216} with antibody positivity increasing with age in Japanese macaques and Japanese domestic pet cats.\textsuperscript{214,216} Although these data show the prevalence of HEV circulation among animals, they have not established the possible role of these animals in transmitting HEV infection to humans. Of particular interest is the high HEV seroprevalence among wild rats,\textsuperscript{208–212} as these rodents, ubiquitous worldwide, have the potential to be infected with swine and human HEV strains. Rats may therefore be an important intermediate host between pigs and humans or, alternatively, a reservoir for both human and swine infection.

The majority of studies on animals other than swine have been more successful in detecting HEV antibodies than viral RNA. Although HEV RNA from genotypes 3 and 4 has been systematically found in pigs, boars, and deer, it has not yet been defined with certainty which genotypes circulate within other species. Two studies document HEV genotype 1 in horses\textsuperscript{217} and pigs.\textsuperscript{218} The finding of HEV genotype 1 in rats\textsuperscript{219} has subsequently been found to be a laboratory error.\textsuperscript{220} More studies are necessary to assess if HEV genotype 1 and 2 strains can induce sustainable infection in some animal species. In view of the large number of animal species that are potentially involved, further exploration of zoonotic transmission of HEV is warranted.\textsuperscript{23}

HEV strains were identified in poultry as well as mammals; phylogenetic analysis indicates that avian HEV is genetically related to, but distinct from, mammalian HEV strains,\textsuperscript{221,222} and does not represent a risk for cross-infection to humans.

### Pathogenesis, immune response, and time course of infection

It is thought that HEV infection initiates via cells lining the alimentary tract (primary site of virus replication) (Figure 4).\textsuperscript{223} The virus then reaches the liver through the portal vein\textsuperscript{31} and replicates in the cytoplasm of hepatocytes without causing direct cytolytic damage.\textsuperscript{224} Several observations suggest that, in analogy with other hepatitis viruses, liver injury is largely immune-mediated:\textsuperscript{150,223,224} first, viraemia precedes the onset of alanine transaminase elevation and liver histopathological changes;\textsuperscript{225–227} secondly, experimental infection of nonhuman primates has shown how the liver damage coincides with the detection of serum anti-HEV antibodies and with a decreasing level of HEV antigens in the hepatocytes;\textsuperscript{150,225} and finally, the lymphocytes infiltrating the liver have a cytotoxic/suppressor immunophenotype.\textsuperscript{150,225}

HEV RNA is detectable in blood from as early as two weeks before\textsuperscript{173} and for two to four weeks after the onset of symptoms.\textsuperscript{228–230} HEV faecal excretion shows a similar temporal pattern.\textsuperscript{229} Once liver function has normalised, HEV RNA is usually undetectable in blood and stool.\textsuperscript{229} Viraemia and faecal shedding beyond the duration of biochemical hepatitis are uncommon,\textsuperscript{229–231} suggesting that prolonged faecal shedding is not important in maintaining the environmental reservoir of HEV.\textsuperscript{229}

The antibody responses are directed primarily against epitopes in the ORF2 and ORF3 proteins and are typically detectable at the onset of the disease, with IgM antibodies persisting for two to six months.\textsuperscript{221,228,212} Anti-HEV IgG appears soon after IgM, and persists for a longer period of time.\textsuperscript{51,223,228,232,231} However, the possibility of repeated infections being the cause of IgG persistence cannot be excluded.\textsuperscript{41}
Overt disease in young adults is commonly the result of primary infection. The importance of antibodies in protecting from clinical hepatitis E has been proven experimentally in primates, in which passive immunisation with anti-HEV antibodies was able to protect them against overt disease after challenge with virulent HEV. Limited data are available on anti-HEV cellular immune response. Evidence for anti-HEV T-cell response was provided by a study on patients with acute hepatitis E whose T-lymphocytes showed sensitisation to HEV peptides. The same group was recently able to map CD4 T-cell epitopes in the ORF2 and ORF3 proteins of HEV using lymphocyte proliferation assays in patients with acute hepatitis E, providing the basis for future studies on the immunopathogenesis of hepatitis E. No data are currently available regarding anti-HEV-specific CD8 T-cell responses or the role of cellular responses in the protection against viral infection.

Of great interest are the mechanisms determining the severity of disease during pregnancy, in which fulminant hepatitis is a common complication. HEV infection studied in pregnant and nonpregnant healthy women has shown that infection in pregnancy is associated with a shift in the Th cell type 1/Th cell type 2 balance toward Th cell type 2 response. However, at this time it is difficult to link the clinical severity of the illness to this observation because the mechanism of liver injury in HEV infection has not yet been clarified. A recent Indian study suggested that a subset of CD4-positive interferon-γ-secreting cells, which do not belong to either the helper Th cell type 1 or type 2 phenotype, might be involved in liver damage during acute HEV infection.

Clinical features
Acute infection
The incubation period ranges from two to 10 weeks with an average of 40 days. Hepatitis E is indistinguishable from other forms of viral hepatitis. Typical clinical features are one- to 10-day prodrome of malaise, fever, gastrointestinal symptoms (abdominal pain, anorexia, nausea, vomiting), followed by the onset of jaundice. Serum investigations reveal raised levels of bilirubin (predominantly conjugated) and alanine aminotransferase. The magnitude of the alanine aminotransferase elevation does not correlate with the severity of the liver injury, better expressed by the liver synthetic function, as determined by coagulation function estimation. Acute infection resolves in one to four weeks; however, some patients develop a more prolonged clinical illness with cholestasis (cholestatic hepatitis). HEV infection is not known to progress to chronicity or cirrhosis in immunocompetent patients.

Complications
A small proportion of patients develop fulminant or subacute hepatic failure with high mortality as a result of
massive liver necrosis. Fulminant hepatitis E has been described worldwide but it is particularly common in developing countries among pregnant women, mainly during the third trimester. In this setting, HEV adversely affects both pregnant women and foetal outcome, with high mortality rate, increased frequency of abortions, preterm delivery, stillbirth, and neonatal death.

In Japan, HEV genotype 4 appears to cause severe hepatitis more frequently than genotype 3, possibly as a consequence of specific genomic mutations. In Argentina, a country not endemic for hepatitis E, fulminant hepatitis has been recently diagnosed in three children infected with HEV genotype 3.

Severe forms of hepatitis E have also been increasingly documented among patients, mainly men, with stable chronic liver disease of different aetiologies, including chronic hepatitis B and C, autoimmune hepatitis, alcoholic liver disease, cryptogenic hepatitis, and Wilson’s disease.

Prolonged mild hepatitis with viral shedding has been described in immunocompromised patients during chemotherapy for T-cell lymphoma. More recently, the evolution of HEV infection into chronic hepatitis E has been reported in solid organ transplant patients in France: they not only persistently shed the virus in the presence of deranged alanine aminotransferase values, but also showed histopathological changes similar to those observed in chronic hepatitis C.

Uncommon HEV infection complications, described in anecdotal reports, include the Guillain–Barre´ syndrome, acute transverse myelitis, acute pancreatitis, non-immune haemolytic anaemia, lymphocytic destructive cholangitis, and prolonged polyarthritis.

Asymptomatic infections

The number of asymptomatic infections far exceeds that of icteric hepatitis, as a large proportion of individuals who test positive for anti-HEV antibodies in highly endemic countries, such as India, China, and Egypt, do not recall having suffered from jaundice. Similar data, based on seroprevalence, have been obtained from a variety of population profiles in developed countries: blood donors in Japan and the USA, prisoners and drug users in Denmark, and individuals living in the community in Spain.

Direct evidence of ongoing subclinical HEV infection in the general population comes from a study conducted in Honshu (Japan) on 6700 asymptomatic blood donors with elevated aminotransferase levels during a three-year period: about 3% of the individuals with an aminotransferase level of $\geq 201\text{IU/l}$ (normal value $< 60\text{IU/l}$) were HEV RNA-positive. Based on the number of asymptomatic viraemic individuals and the incidence of hepatitis E in Honshu, the authors estimate that less than 0.1% of HEV-infected cases exhibit clinical manifestation of the infection. Asymptomatic viraemia has been detected in about 0.3% of individuals in rural eastern China.

Diagnosis

Antibody detection

HEV antibody assays represent the routine diagnostic tool for acute hepatitis E cases. Test formats mostly consist of indirect enzyme-linked immunosorbent assays (EIA), with recombinant HEV proteins or peptides as detecting antigens. Currently available commercial assays are based mainly on HEV epidemic strains but EIA tests specific for genotypes 3 and 4 have also been developed. The specificity and sensitivity of these tests have not been established with precision, limiting the reliability of laboratory results.

One of the most widely available commercial antibody assays, the Genelabs-EIA, uses short recombinant proteins derived from the 3’ termini of ORF2 (42 amino acids) and ORF3 (33 amino acids) from the Burmese (genotype 1) and Mexican (genotype 2) prototype sequences. However, according to Zhou et al., a truncated form of the ORF2 protein, encompassing amino acids 112–607, contains the neutralisation epitopes (with amino acids 458–607 representing the major neutralisation site) and elicits the greatest and most long-lasting anti-HEV antibody response, being therefore suitable both for diagnostic and seroprevalence estimation purposes. In contrast, the amino acids 1–111 (N-terminus) and 607–660 (C-terminus) of the ORF2 protein and the ORF3 recombinant antigens elicit a weaker and transient antibody response, and are consequently of limited value in diagnosing acute HEV infection, and are not useful for seroprevalence studies. Importantly, all genotypes share at least one major serologically crossreactive epitope, despite substantial genomic variability.

Diagnosis of acute hepatitis E is made by detecting HEV-specific IgM in acute-phase sera or by detecting a rise in anti-HEV IgG titre between acute and convalescent serum samples. Cases of aberrant IgM and IgG serological profiles, including those with immunologically silent acute hepatitis E, have been documented. Although atypical serological profiles from patients with proven HEV RNA viraemia may be the expression of a modified immune response, the insensitivity of diagnostic assays should be taken into account when interpreting these data.

Molecular detection

Reverse transcription-polymerase chain reaction (RT-PCR) assays represent the most commonly used molecular investigation for HEV genome detection. The usage of RT-PCR as a diagnostic tool has become feasible since the development of the real-time PCR platforms, closed systems that minimise the risk of contamination by the amplified target.

The majority of HEV RT-PCR assays used for diagnosis were developed as in-house assays by choosing different conserved HEV genomic regions as the target for amplifica-
Considering the wide genetic heterogeneity of HEV isolates, it is critical to design primers and probes that guarantee the development of highly sensitive and broadly reactive assays.\(^\text{268}\)

RT-PCR is a useful complementary diagnostic tool for the diagnosis of acute HEV infection, as it can confirm cases of hepatitis E with atypical serological profiles. RT-PCR assays are also critically important for public health purposes when used for detecting HEV-contaminated environmental samples.

### Prevention and control of the infection

#### Active immunisation

The observation that passive immune prophylaxis with convalescent serum samples prevented hepatitis E in primates has indicated that vaccination against HEV based on humoral immunity is feasible.\(^\text{55,235,269}\) This has prompted HEV immunisation studies based mainly on recombinant proteins, because the unavailability of an efficient cell culture system for HEV replication\(^\text{270}\) has precluded the development of vaccines based on inactivated or attenuated whole-virus particles. However, other approaches, such as DNA-based vaccines,\(^\text{271,272}\) able to induce both cellular and antibody response, are also under evaluation.

The ORF2 protein has been considered the best candidate for HEV vaccine because it contains the neutralisation epitope located between amino acids 458 and 607\(^\text{56}\) and is crossreactive with all mammalian HEV.\(^\text{56,273}\) Animal studies have shown that ORF2 recombinant proteins\(^\text{274-278}\) elicit neutralising antibodies and mediate protective immunity in vaccinated primates.\(^\text{277,279}\)

One such vaccine with a 56 kDa protein encompassing amino acids 112–607\(^\text{55,280}\) was recently evaluated in young adults in Nepal in a phase 2, randomised, double-blind, placebo-controlled trial.\(^\text{281}\) The study had encouraging results establishing that three doses of hepatitis E vaccine were 95.5% effective in protecting against clinical hepatitis E after a median of 804 days. The primary endpoint of this study was the prevention of clinically overt HEV infection, but the ability of the vaccine to prevent asymptomatic infection and asymptomatic virus shedding was not investigated.\(^\text{174}\) Asymptomatic HEV shedding in vaccine recipients, shown previously in primates,\(^\text{280}\) may be relevant in maintaining the environmental reservoir of HEV for human infection.\(^\text{174}\) Another aspect that this trial could not clarify is the duration of the induced immunity. Based on currently available data, this vaccine may be useful for travellers to highly endemic areas and for susceptible pregnant women,\(^\text{174}\) particularly during outbreaks. However, its use in children and adolescents in hepatitis E endemic countries,\(^\text{174}\) or in individuals with chronic liver disease, requires further study assessing the duration of its protective efficacy.

#### Protection of the environment and control of the outbreaks

The most important measure to prevent HEV infection is the protection of water supply from faecal contamination.

### Table 1  Clinical–epidemiological characteristics of HEV infection

| HEV Genotypes | Geographical distribution | Hosts | Mode of transmission | Epidemic versus sporadic forms | Clinical attack rate | Disease severity |
|----------------|---------------------------|-------|----------------------|-------------------------------|---------------------|----------------|
| 1              | Asia, Africa              | Humans | Contamination of water supply | Sporadic and epidemic forms | Highest in young adults | Highest in pregnant women and individuals with chronic liver disease |
| 2              | Central America, Africa   | Humans and a variety of animals, particularly swine | Food (Japan) | Sporadic and small outbreaks | Highest in older males | Highest in individuals with chronic liver disease |
| 3              | Asia, America, Europe, Oceania | Humans and a variety of animals, particularly swine | Food (Japan), Environmental contamination by swine waste | Highest in older males | Highest in individuals with chronic liver disease |

Abbreviation: HEV, hepatitis E virus. Zoonotic strains (HEV genotype 3 and 4) cause infection both in developed and in developing countries (in italics), such as China.
Chlorination and filtration systems are generally inadequate if the source water is heavily contaminated.\textsuperscript{223} Travellers to highly endemic regions should strictly consume only bottled or boiled water.

During outbreaks, it is critical to provide clean water to all pregnant women. The isolation of individuals affected by acute hepatitis E is not justified because person-to-person transmission is uncommon. Infected people should refrain from food handling and food preparation.\textsuperscript{223}

**Conclusion**

HEV infection has complex, and not yet completely clarified, clinical-epidemiological characteristics, which are summarised in Table 1. Two forms of infection have been identified: hepatitis E caused by epidemic strains, affecting mainly young adults and particularly pregnant women, and hepatitis E caused by zoonotic strains, which mostly affect older males.\textsuperscript{282} These differences in sex- and age-specific attack rates are puzzling because the route of transmission in developed countries, apart from Japan, has not yet been identified.

More extensive epidemiological studies are needed, not only to assess the HEV seroprevalence in humans, but also in several animal species. For this purpose, the development of broadly reactive reliable antibody assays, which include immunodominant neutralisation antigens, is critical. Equally important is to establish which HEV genotypes circulate among the different animal species, and their role in human infections.

A high level of suspicion is needed in developed countries where the increasing number of recognised cases of hepatitis E\textsuperscript{16,18,106–102} suggests significant underdiagnosis.\textsuperscript{100} Awareness of HEV infection should exist in immunocompromised patients with signs of liver damage in view of the recent finding that hepatitis E can evolve to a chronic infection.\textsuperscript{255,256}

The results of a HEV vaccination phase 2 trial have provided encouraging preliminary data for the prevention of hepatitis E.\textsuperscript{281} Data are now awaited regarding the duration of the immune response induced by the vaccine before routine immunisation of children can be promoted in epidemic countries. It will also be important to establish the vaccine efficacy among older adults and the elderly, who are targets of overt HEV infection and in whom most cases of chronic liver disease, a risk factor for severe hepatitis E, concentrate.

**Acknowledgements**

*Competing interest*

The authors state no competing interests.

*Provenance and peer review*

Commissioned without payment, externally peer-reviewed.

**References**

1. Wong DC, Purcell RH, Sreenivasan MA, Prasad SR, Pavri KM. Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet 1980;2:876–9.
2. Khuroo MS, Saleem M, Teli MR, Sofi MA. Failure to detect chronic liver disease after epidemic non-A, non-B hepatitis. Lancet 1980;2:97–8.
3. Jary C. Hepatitis E and meat carcasses. Br J Gen Pract 2005;55:557–558.
4. Boccia D, Guthmann JP, Klovstad H, Hamid N, Tatay M, Ciglenecki I, et al. High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis 2006;42:1679–84.
5. Banait VS, Sandur V, Parikh F, Murugesh M, Ranka P, Ramesh VS, et al. Outcome of acute liver failure due to acute hepatitis E in pregnant women. Indian J Gastroenterol 2007;26:6–10.
6. Reuter G, Fodor D, Szucs G. Molecular detection of hepatitis E virus in non-imported hepatitis E cases: identification of a potential new human hepatitis E virus lineage in Hungary. Orv Hetil 2005;146:2389–94. [article in Hungarian].
7. Preiss JC, Plenzts A, Engelmann E, Schneider T, Jilg W, Zeitz M, et al. Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection 2006;24:173–5.
8. Widowson MA, Jaspers WJ, van der Poel WH, Verschoor F, de Roda Husman AM, Winter HL, et al. Cluster of cases of acute hepatitis associated with hepatitis E virus infection acquired in The Netherlands. Clin Infect Dis 2003;36:29–33.
9. Worm HC, Wurzer H, Frosner G. Sporadic hepatitis E in Austria. N Engl J Med 1998;339:1534–5.
10. Mansuy JM, Peron JM, Abravanel F, Poznac H, Dubois M, Miedouge M, et al. Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol 2004;74:419–24.
11. Dalton HR, Fellows HJ, Gane EJ, Wong P, Gerred S, Schroeder B, et al. Hepatitis E in New Zealand. J Gastroenterol Hepatol 2007;22:1236–40.
12. Schlauder GG, Desai SM, Zanetti AR, Tassopoulos NC, Mushahwar IK. Novel hepatitis E virus (HEV) isolates from Europe: evidence for additional genotypes of HEV. J Med Virol 1999;57:243–51.
13. Schlauder GG, Dawson GJ, Erker JC, Kwo PY, Knigge MF, Smalley DL, et al. The sequence and phylogenetic analysis of a novel hepatitis E virus isolated from a patient with acute hepatitis reported in the United States. J Gen Virol 1999;79(Pt 3):447–56.
14. Teo CG. Hepatitis E indigenous to economically developed countries: to what extent a zoonosis? Curr Opin Infect Dis 2006;19:460–6.
15. Zanetti AR, Schlauder GG, Romano I, Tanzi E, Fabris P, Dawson GJ, et al. Identification of a novel variant of hepatitis E virus in Italy. J Med Virol 1999;57:356–60.
16. Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis 2005;192:1166–72.
17. Amon JJ, Drobeniuc J, Bower WA, Magana JC, Escobedo MA, Williams IT, et al. Locally acquired hepatitis E virus infection, El Paso, Texas. J Med Virol 2006;78:741–6.
18. Dalton HR, Thurairajah PH, Fellows HJ, Russaini HS, Mitchell J, Bendall R, et al. Autochthonous hepatitis E in southwest England. J Viral Hepat 2007;14:304–9.
19. Clemente-Casares P, Pina S, Buti M, Jardi R, Martin M, Bofill-Mas S, et al. Hepatitis E virus epidemiology in industrialized countries. Emerg Infect Dis 2003;9:448–54.
20. Buti M, Clemente-Casares P, Jardi R, Formiga-Cruz M, Schaper M, Valdes A, et al. Sporadic cases of acute autochthonous hepatitis E in Spain. J Hepatol 2004;41:126–31.
21 McCrudden R, O’Connell S, Farrant T, Beaton S, Iredale JP, Fine D. Sporadic acute hepatitis E in the United Kingdom: an underdiagnosed phenomenon? *Gut* 2000; 46:732–3.

22 Levine DF, Bendall RP, Teo CG. Hepatitis E acquired in the UK. *Gut* 2000; 47:740.

23 Mizuo H, Yazaki Y, Sugawara K, Tsuda F, Takahashi M, Nishizawa Y, et al. Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido, Japan. *J Med Virol* 2005; 76:341–9.

24 Okamoto H, Takahashi M, Nishizawa T. Features of hepatitis E virus infection in Japan. *Intern Med* 2003; 42:1065–71.

25 Mizuo H, Suzuki K, Takikawa Y, Sugai Y, Tokita H, Akahane Y, et al. Polyphyletic strains of hepatitis E virus are responsible for sporadic cases of acute hepatitis in Japan. *J Clin Microbiol* 2002; 40:2309–18.

26 Kwo PY, Schlauder GG, Carpenter HA, Murphy PJ, Rosenblatt JE, et al. Sporadic acute hepatitis E in the United Kingdom: an underdiagnosed phenomenon? *D. Sporadic acute hepatitis E in the United Kingdom: an underdiagnosed phenomenon? Gut* 2000; 46:732–3.

27 Levine DF, Bendall RP, Teo CG. Hepatitis E acquired in the United States. *Mayo Clin Proc* 1997; 72:1133–6.

28 Herremans M, Vennema H, Bakker J, van der Vee B, Duizer E, Benne CA, et al. Swine-like hepatitis E viruses are a cause of unexplained hepatitis E in The Netherlands. *J Virol Hepat* 2007; 14:140–6.

29 Zheng Y, Ge S, Zhang J, Guo Q, Ng MH, Wang F, et al. Swine as a principal reservoir of hepatitis E virus that infects humans in eastern China. *J Infect Dis* 2006; 193:1643–9.

30 Tanaka Y, Takahashi K, Orito E, Karino Y, Kang JH, Suzuki K, et al. Molecular tracing of Japan-indigenous hepatitis E viruses. *J Gen Virol* 2006; 87 (Pt 4): 949–54.

31 Feagins AR, Oppriessnig T, Guenette DK, Halbur PG, Meng XJ. Detection and characterization of infectious hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. *J Gen Virol* 2007; 88 (Pt 3): 912–17.

32 Jung K, Kang B, Song DS, Chae C. Prevalence and genotyping of hepatitis E virus in swine population in Korea between 1995 and 2004: a retrospective study. *Vet J* 2007; 173:683–7.

33 Munne MS, Vladimírsky S, Otegui L, Castro R, Brajterman L, Soto S, et al. Identification of the first strain of swine hepatitis E virus in South America and prevalence of anti-HEV antibodies in swine in Argentina. *J Med Virol* 2006; 78:1579–83.

34 Cooper K, Huang FF, Batista I, Rayo CD, Bezanilla JC, Toth TE, et al. Identification of genotype 3 hepatitis E virus (HEV) in serum and fecal samples from pigs in Thailand and Mexico, where genotype 1 and 2 HEV strains are prevalent in the respective human populations. *J Clin Microbiol* 2005; 43:1684–8.

35 Banks M, Heath GS, Grierson SS, King DP, Gresham A, Girones R, et al. Evidence for the presence of hepatitis E virus in pigs in the United Kingdom. *Vet Rec* 2004; 154:223–7.

36 van der Poel WH, Verschoor F, van der Heide R, Herrera MI, Vivo et al. Infection of pigs with HEV and prevalence of anti-HEV antibodies in a swine population in Korea between 1995 and 2005: a retrospective study. *Hepatol Res* 2003; 17:501–5.

37 Tyrén M, Jameel S, Lal SK. The ORF2 protein of hepatitis E virus binds the S' region of viral RNA. *J Virol* 2004; 78:320–8.
60 Tyagi S, Korkaya H, Zafraullah M, Jameel S, Lal SK. The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-phosphorylated form of the major capsid protein, ORF2. J Biol Chem 2002;277:22759–67.

61 Zafraullah M, Ozdener MH, Panda SK, Jameel S. The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton. J Virol 1997;71:5945–53.

62 Emerson SU, Purcell RH. Hepatitis E virus. Rev Med Virol 2003;13:145–54.

63 Korkaya H, Jameel S, Gupta D, Tyagi S, Kumar R, Zafraullah M, et al. The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK. J Biol Chem 2001;276:42389–400.

64 Huang YW, Opiessing T, Halbur PG, Meng XJ. Initiation at the third in-frame AUG codon of open reading frame 3 of the hepatitis E virus is essential for viral infectivity in vivo. J Virol 2007;81:3018–26.

65 Emerson SU, Nguyen H, Torian U, Purcell RH, ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro. J Virol 2006;80:10457–64.

66 Agrawal S, Gupta D, Panda SK. The 3’ end of hepatitis E virus (HEV) genome binds specifically to the viral RNA-dependent RNA polymerase (RdRp). Virology 2001;282:87–101.

67 Emerson SU, Arankalle VA, Purcell RH. Thermal stability of hepatitis E virus. J Infect Dis 2001;183:930–3.

68 Tanaka T, Takahashi M, Kusano E, Okamoto H. Development and evaluation of an efficient cell-culture system for hepatitis E virus. J Gen Virol 2007;88 (Pt 3): 903–11.

69 Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 2006;16:5–36.

70 Zhai L, Dai X, Meng J. Hepatitis E virus genotyping based on full-length genome and partial genomic regions. Virus Res 2006;120:57–69.

71 Huang R, Li D, Wei S, Li Q, Yuan X, Geng L, et al. Cell culture of sporadic hepatitis E virus in China. Clin Diagn Lab Immunol 1999;6:729–33.

72 Wei S, Walsh P, Huang R, To SS. 93G, a novel sporadic strain of hepatitis E virus in South China isolated by cell culture. J Med Virol 2000;61:111–18.

73 Tam AW, White R, Reed E, Short M, Zhang Y, Fuerst TR, et al. In vitro propagation and production of hepatitis E virus from in vivo-infected primary macaque hepatocytes. Virology 1996;218:1–11.

74 Emerson SU, Clemente-Casares P, Moiduddin N, Arankalle VA, Torian U, Purcell RH. Putative neutralization epitopes and broad neutralization of hepatitis E virus confirmed by a quantitative cell-culture assay. J Gen Virol 2006;87 (Pt 3): 697–704.

75 Jameel S, Zafraullah M, Chawla YK, Dilawari JB. Reevaluation of a North India isolate of hepatitis E virus based on the full-length genomic sequence obtained following long RT-PCR. Virus Res 2002;86:53–8.

76 Aggarwal R, McCaustland KA, Dilawari JB, Sinha SD, Robertson BH. Genetic variability of hepatitis E virus within and between three epidemics in India. Virus Res 1999;59:35–48.

77 Arankalle VA, Faranjape S, Emerson SU, Purcell RH, Waliembe AM. Phylogenetic analysis of hepatitis E virus isolates from India (1976–1993). J Gen Virol 1999;80 (Pt 7): 1691–700.

78 Vaidya SR, Chitambar SD, Arankalle VA. Polymerase chain reaction-based prevalence of hepatitis A, hepatitis E and TT viruses in sewage from an endemic area. J Hepatol 2002;37: 131–136.

79 Tsarev SA, Emerson SU, Reyes GR, Tsareva TS, Legters JI, Malik cytoskeleton. Virus Res 2002;85:59–63.

80 Shrestha SM, Shrestha S, Tsuda F, Nishizawa T, Gotanda Y, et al. Characterization of a prototype strain of hepatitis E virus. Proc Natl Acad Sci USA 1992;89:559–63.

81 Shrestha SM, Shrestha S, Tsuda F, Nishizawa T, Takahashi M, Gotanda Y, et al. Genetic changes in hepatitis E virus of subtype 1a in patients with sporadic acute hepatitis E in Kathmandu, Nepal, from 1997 to 2002. J Gen Virol 2004;85 (Pt 1): 97–104.

82 Debnick JJ, Gambhir VS, Caudill JD, Sun W, Hoke Jr CH, et al. A cluster of acute hepatitis E infection in United Nations Bangladeshi peacekeepers in Haiti. Am J Trop Med Hyg 1997;57:449–54.

83 Bi SL, Purdy MA, McCaustland KA, Margolis HS, Bradley DW. The sequence of hepatitis E virus isolated directly from a single source during an outbreak in China. Virus Res 1993;28:233–47.

84 Wang Y, Zhang H, Li Z, Gu W, Lan H, Hao W, et al. Detection of sporadic cases of hepatitis E virus (HEV) infection in China using immunosassays based on recombinant open reading frame 2 and 3 polypeptides from HEV genotype 4. J Clin Microbiol 2001;39: 4370–4379.

85 Yin S, Purcell RH, Emerson SU. A new Chinese isolate of hepatitis E virus: comparison with strains recovered from different geographical regions. Virus Genes 1994;9:23–32.

86 Lu L, Drobenic J, Kobylinikov N, Usmanov RK, Robertson BH, Favorov MO, et al. Complete sequence of a Kyrgyzstan swine hepatitis E virus (HEV) isolate from a piglet thought to be experimentally infected with human HEV. J Med Virol 2004;75: 556–562.

87 Chatterjee R, Tsarev S, Pillott J, Coursaget P, Emerson SU, Purcell RH. African strains of hepatitis E virus that are distinct from Asian strains. J Med Virol 1997;53:139–44.

88 Tsarev SA, Binn LN, Gamatos PJ, Arthur RR, Monier MK, van Cuyck-Gandre H, et al. Phylogenetic analysis of hepatitis E virus isolates from Egypt. J Med Virol 1999;57:68–74.

89 Grandadam M, Tebhal S, Caron M, Sinwardana M, Larouze B, Koeck JL, et al. Evidence for hepatitis E virus quasispecies. J Gen Virol 2004;85 (Pt 11): 3189–94.

90 He J, Binn LN, Tsarev SA, Hayes CG, Freen JA, Isaacson M, et al. Molecular characterization of a hepatitis E virus isolate from Namibia. J Biomed Sci 2000;7:334–8.

91 Nicand E, Armstrong GL, Enouf V, Gathmann JP, Guerin JP, Caron M, et al. Genetic heterogeneity of hepatitis E virus in Darfur, Sudan, and neighboring Chad. J Med Virol 2005;77: 519–21.

92 van Cuyck H, Juge F, Roques P. Phylogenetic analysis of the first complete hepatitis E virus (HEV) genome from Africa. FEMS Immunol Med Microbiol 2003;39:133–40.

93 Huang CC, Nguyen D, Fernandez J, Yen KY, Fry KE, Bradley DW, et al. Molecular cloning and sequencing of the Mexico isolate of hepatitis E virus (HEV). Virology 1992;191:550–8.

94 Buisson Y, Grandadam M, Nicand E, Cheval P, van Cuyck-Gandre H, Innis B, et al. Identification of a novel hepatitis E virus in Nigeria. J Gen Virol 2000;81 (Pt 4): 903–9.

95 Maila HT, Bowyer SM, Swanepool R. Identification of a new strain of hepatitis E virus from an outbreak in Namibia in 1995. J Gen Virol 2004;85 (Pt 1): 89–95.

96 Huang F, Haqshenas G, Guenther DK, Halbur PG, Schommer SK, Pierson FW, et al. Detection by reverse transcription-PCR and genetic characterization of field isolates of swine hepatitis E virus from pigs in different geographic regions of the United States. J Clin Microbiol 2002;40:1326–32.

97 Kabrane-Lazizi Y, Zhang M, Purcell RH, Miller KD, Davey RT, Emerson SU. Acute hepatitis E virus most closely related to United States strains. J Gen Virol 2001;82 (Pt 7): 1687–93.

98 Leblanc D, Ward P, Gagne MJ, Poitras E, Muller P, Trottier YL, et al. Presence of hepatitis E virus in a naturally infected swine herd from nursery to slaughter. Int J Food Microbiol 2007;177: 160–166.

99 Munne MS, Vladimirska S, Otegui L, Brajerman L, Castro R, Soto S, et al. Molecular characterization of hepatitis E virus in...
three acute liver failure cases in children in Argentina. *Acta Gastroenterol Latinoam* 2006;36:125–30.
100 Lewis H, Morgan D, Ijaz S, Boxall E. Indigenous hepatitis E virus infection in England and Wales. *BMJ* 2006;332:1509–10.
101 De Silva AN, Muddu AK, Iredale JP, Sheron N, Khakoo SJ, Pelosi E. Unexpectedly high incidence of indigenous acute hepatitis E within South Hampshire: time for routine testing? *J Med Virol* 2008;80:283–8.
102 Peron JM, Mansuy JM, Poirson H, Bureau C, Dupuis E, Alric L, *et al.* Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. *Gastroenterol Clin Biol* 2006;30:757–70.
103 Takahashi K, Kang JH, Ohnishi S, Hino K, Mishiro S. Genetic heterogeneity of hepatitis E virus recovered from Japanese patients with acute sporadic hepatitis. *J Infect Dis* 2002;185:1342–5.
104 Takahashi K, Iwata K, Watanabe N, Hatahara T, Ohta Y, Baba K, *et al.* Full-genome nucleotide sequence of a hepatitis E virus strain that may be indigenous to Japan. *Virology* 2001;287:9–12.
105 Matsubayashi K, Nagao Y, Sakata H, Sato S, Fukai K, Kato T, *et al.* Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. *Transfusion* 2004;44:934–40.
106 Takahashi M, Nishizawa T, Okamoto H. Identification of a genotype III swine hepatitis E virus that was isolated from a Japanese pig born in 1990 and that is most closely related to Japanese isolates of human hepatitis E virus. *J Clin Microbiol* 2003;41:1342–3.
107 Okamoto H, Takahashi M, Nishizawa T, Fukai K, Muramatusu, Yoshikawa A. Analysis of the complete genome of indigenous swine hepatitis E virus isolated in Japan. *Biochim Biophys Res Commun* 2001;289:929–36.
108 Tokita H, Harada H, Gotanda Y, Takahashi M, Nishizawa T, Okamoto H. Molecular and serological characterization of sporadic acute hepatitis E in a Japanese patient infected with a genotype III hepatitis E virus in 1993. *J Gen Virol* 2003;84 (Pt 2): 421–7.
109 Takahashi M, Nishizawa T, Miyajima H, Gotanda Y, Iita T, Tsuda F, *et al.* Swine hepatitis E virus strains in Japan form four phylogenetic clusters comparable with those of Japanese isolates of human hepatitis E virus. *J Gen Virol* 2003;84 (Pt 4): 851–62.
110 Tamada Y, Yano K, Yatsuhashi H, Inoue O, Kawatari F, Ishibashi H. Consumption of wild boar linked to cases of hepatitis E. *J Hepatol* 2004;40:809–70.
111 Ning H, Yu S, Zhu Y, Dong S, Yu R, Shen S, *et al.* Genotype 3 hepatitis E has been widespread in pig farms of Shanghai suburbs. *Vet Microbiol* 2008;126:257–63.
112 Arakalle VA, Chobe LP, Joshi MV, Chadha MS, Kundu B, Walimbe AM. Human and swine hepatitis E viruses from Western India belong to different genotypes. *J Hepatol* 2002;36:417–25.
113 Arakalle VA, Chobe LP, Walimbe AM, Yergolkar PN, Jacob GP. Swine HEV infection in south India and phylogenetic analysis (1985–1999). *J Med Virol* 2003;69:391–6.
114 Li K, Zhuang H, Zhu W. Partial nucleotide sequencing of hepatitis E viruses detected in sera of patients with hepatitis E from 14 cities in China. *Clin Med J (Engl)* 2002;115:1058–63.
115 Wang YC, Zhang HY, Xia NS, Peng G, Lan HY, Zhuang H, *et al.* Prevalence, isolation, and partial sequence analysis of hepatitis E virus from domestic animals in China. *J Med Virol* 2002;67:516–21.
116 Nishizawa T, Takahashi M, Mizuo H, Miyajima H, Gotanda Y, Okamoto H. Characterization of Japanese swine and human hepatitis E virus isolates of genotype IV with 99% identity over the entire genome. *J Gen Virol* 2003;84 (Pt 5): 1245–51.
117 Wibawa ID, Muljono DH, Mulyanto, Suryadarma IG, Tsuda F, Takahashi M, *et al.* Prevalence of antibodies to hepatitis E virus among apparently healthy humans and pigs in Bali, Indonesia: identification of a pig infected with a genotype 4 hepatitis E virus. *J Med Virol* 2004;73:38–44.
118 Hijikata M, Hayashi S, Trinh NT, Ha le D, Ohara H, Shimizu YK, *et al.* Genotyping of hepatitis E virus from Vietnam. *Interl virology* 2002;45:101–4.
119 Inoue J, Nishizawa T, Takahashi M, Aikawa T, Mizuo H, Suzuki K, *et al.* Analysis of the full-length genome of genotype 4 hepatitis E virus isolates from patients with fulminant or acute self-limited hepatitis E. *J Med Virol* 2006;78:476–84.
120 Ahn JM, Kang SG, Lee DY, Shin SJ, Yoo HS. Identification of novel human hepatitis E virus (HEV) isolates and determination of the seroprevalence of HEV in Korea. *J Clin Microbiol* 2005;43:3042–8.
121 Suzuki K, Aikawa T, Okamoto H. Fulminant hepatitis E in Japan. *N Engl J Med* 2002;347:1456.
122 Takahashi M, Nishizawa T, Yoshikawa A, Sato S, Isoda N, Ido K, *et al.* Identification of two distinct genotypes of hepatitis E virus in a Japanese patient with acute hepatitis who had not travelled abroad. *J Gen Virol* 2002;83 (Pt 8): 1931–40.
123 Michitaka K, Takahashi K, Furukawa S, Inoue G, Hiasa Y, Horiike N, *et al.* Prevalence of hepatitis E virus among wild boar in the Ehime area of western Japan. *Hepatol Res* 2007;37:214–20.
124 Martelli F, Caprioli A, Zengarini M, Marata A, Fiegna C, Di Bartolo I, *et al.* Detection of hepatitis E virus (HEV) in a demographic managed wild boar (*Sus scrofa scrofa*) population in Italy. *Vet Microbiol* 2008;126:74–81.
125 Banks M, Bendall R, Griersson S, Heath G, Mitchell J, Dalton H. Human and porcine hepatitis E virus strains, United Kingdom. *Emerg Infect Dis* 2004;10:953–5.
126 Pei Y, Yoo D. Genetic characterization and sequence heterogeneity of a Canadian isolate of swine hepatitis E virus. *Clin Microbiol Rev* 2005;18:4021–9.
127 Shukla P, Chauhan UK, Naik S, Anderson D, Aggarwal R. Hepatitis E virus infection among animals in northern India: an unlikely source of human disease. *J Viral Hepat* 2007;14:310–17.
128 Arakalle VA, Lole KS, Deshmukh TM, Chobe LP, Gandhe SS. Evaluation of human (genotype 1) and swine (genotype 4)-ORF2-based ELISAs for anti-HEV IgM and IgG detection in an endemic country and search for type 4 human HEV infections. *J Viral Hepat* 2007;14:435–45.
129 Chobe LP, Lole KS, Arakalle VA. Full genome sequence and analysis of Indian swine hepatitis E virus isolate of genotype 4. *Vet Microbiol* 2006;114:240–51.
130 Jothikumar N, Aparna K, Kamatchiammal S, Paulmurugan R, Saravanadevi S, Khanna P. Detection of hepatitis E virus in raw and treated wastewater with the polymerase chain reaction. *Appl Environ Microbiol* 1993;59:2558–62.
131 Pina S, Jofre J, Emerson SU, Purcell RH, Girones R. Characterization of a strain of infectious hepatitis E virus isolated from sewage in an area where hepatitis E is not endemic. *Appl Environ Microbiol* 1998;64:4485–8.
132 Li TC, Miyamura T, Takeda N. Detection of hepatitis E virus RNA from the bivalve *Yamato-Shijimi* (*Corbicula japonica*) in Japan. *Am J Trop Med Hyg* 2007;76:170–2.
133 Li TC, Chijiwa K, Sera N, Ishibashi T, Etoh Y, Shinohara Y, *et al.* Hepatitis E virus transmission from wild boar meat. *Emerg Infect Dis* 2005;11:1958–60.
134 Tei S, Kitajima N, Ohara S, Inoue Y, Miki M, Yamatani T, *et al.* Consumption of uncooked deer meat as a Risk factor for hepatitis E virus infection: an age- and sex-matched case-control study. *J Med Virol* 2004;74:67–70.
135 Arakalle VA, Chadha MS, Mehendale SM, Tungatkar SP. Epidemic hepatitis E: serological evidence for lack of intrafamilial spread. *Indian J Gastroenterol* 2000;19:24–8.
136 Naik SR, Aggarwal R, Salunke PN, Mehrotra NN. A large waterborne viral hepatitis E epidemic in Kanpur, India. *Bull World Health Organ* 1992;70:597–604.
137 Aggarwal R, Naik SR. Hepatitis E: intrafamilial transmission versus waterborne spread. J Hepatol 1994;21:718–23.

138 Somani SK, Aggarwal R, Naik SR, Srivastava S, Naik S. A serological study of intrafamilial spread from patients with sporadic hepatitis E virus infection. J Viral Hepat 2003;10:446–9.

139 Ducancelle A, Payan C, Nicand E, Le Guillou H, Cales F, Lune-Fabiani E. Intrafamilial hepatitis E in France. J Clin Virol 2007;39:51–3.

140 Gotanda Y, Iwata A, Ohnuma H, Yoshikawa A, Mizoguchi H, Endo K, et al. Ongoing subclinical infection of hepatitis E virus among blood donors with an elevated alanine aminotransferase level in Japan. J Med Virol 2007;79:734–42.

141 Mitsui T, Tsukamoto Y, Suzuki S, Yamazaki C, Masuko K, Tsuda F, et al. Serological and molecular studies on subclinical hepatitis E virus infection using periodic serum samples obtained from healthy individuals. J Med Virol 2005;76:526–33.

142 Khuroo MS, Kamilli S, Yattoo GN. Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. J Gastroenterol Hepatol 2004;19:778–84.

143 Tamura A, Shimizu YK, Tanaka T, Kuroda K, Arakawa Y, Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E virus infection in pregnant women in the United Arab Emirates. J Obstet Gynecol Reprod Biol 2003;18:411–5.

144 Khuroo MS, Kamilli S, Jameel S. Study of an epidemic of non-A, non-B hepatitis. Hepatol Res 2007;37:113–20.

145 Nakano Y, Yamauchi A, Shimizu Y, Nakayama O, Sakai H, Nagasaka Y, et al. A diffuse outbreak of hepatitis E in Mie Prefecture, 2005. Jpn J Infect Dis 2006;59:135–6.

146 Sainokami S, Abe K, Kumagai I, Miyasaka A, Endo R, Takikawa Y, et al. Epidemiological and clinical study of sporadic acute hepatitis E caused by indigenous strains of hepatitis E virus in Japan compared with acute hepatitis A. J Gastroenterol Hepatol 2004; 39:e40–8.

147 Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possible origin of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980;68:818–24.

148 Kane MA, Bradley DW, Shrestha SM, Maynard JE, Cook EH, Mishra RP, et al. Epidemiological aspects of hepatitis E virus in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984;252:3140–5.

149 Tsega E, Hansson BG, Krawczynski K, Aetiology of acute sporadic non-A, non-B viral hepatitis in Ethiopia: causes, risk factors, and effects on pregnancy. Clin Infect Dis 1992;14:961–5.

150 Aggarwal R, Krawczynski K. Hepatitis E: an overview and recent developments. Indian J Med Res 2006;124:45–9.

151 Gupta RK, et al. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J Gastroenterol Hepatol 2007;22:676–82.

152 Kumar AS, Kumar SP, Singh R, Kumar MS, Madan K, Kumar JJ, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Med Virol 2007;4:387–94.

153 Khuroo MS, Aggarwal R, Naik SR, Sarawat V, Ghoshal UC, Naik S. Hepatitis E virus is responsible for decompensation of chronic liver disease in an endemic area. Indian J Gastroenterol 2004;23:59–62.

154 Monga R, Garg S, Tyagi P, Kumar N. Superimposed acute hepatitis E in patients with chronic liver disease. Indian J Gastroenterol 2004;23:50–2.

155 Ramachandran J, Eappen CE, Karg G, Abraham P, Hubert DD, Kurian G, et al. Hepatitis E virus infection and fulminant hepatic failure in patients with chronic liver disease. J Hepatol 2004;40:134–8.

156 Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002;36:474–8.

157 Kc S, Mishra AK, Shrestha R. Hepatitis E virus infection in chronic liver disease causes rapid decompensation. JAMA 2006;295:212–15.

158 Dalton HR, Hazeldine S, Banks M, Izaj S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet 2007;369:1260.

159 Christensen PB, Engle RE, Jacobsen SK, Kraup HB, Georgsen J, Purcell RH. High prevalence of hepatitis E antibodies among Danish prisoners and drug users. J Med Virol 2002;64:49–55.

160 Nicolai G, Grandadam M, Teyssou R, Rey JL, Buisson Y. Viraemia and faecal shedding of HEV in symptom-free carriers. Lancet 2001;357:68–9.

161 Krawczynski K. Hepatitis E vaccine—ready for prime time? N Engl J Med 2007;356:949–51.

162 Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine 2004;22:2578–85.

163 Ghabrah TM, Tsarev S, Yarboough PO, Emerson SU, Strickland GT, Purcell RH. Comparison of tests for antibodies to hepatitis E virus. J Med Virol 1998;58:134–7.

164 Arankalle VA, Tsarev SA, Chada MS, Alling DW, Emerson SU, Strickland et al. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis 2006;42:1685–91.

165 Abba MK, Bile MK, Muhibik MM, Asghar H, Sami Z, Siddiqi S, et al. Water-borne hepatitis E virus epidemic in Islamabad, Pakistan: a common source outbreak traced to the malfunction of a modern water treatment plant. Am J Trop Med Hyg 1997;57:151–7.

166 Sanyal MC. Hepatitis E virus infection amongst personnel of the armed forces, Delhi (1955–56): epidemiology. Indian J Med Res 1957;45 (Suppl): 91–9.

167 Khan RK, et al. Hepatitis E virus infection and fulminant hepatic failure in patients with chronic liver disease. Indian J Gastroenterol 2004;23:59–62.

168 Ghabrah TM, Tsarev S, Yarboough PO, Emerson SU, Strickland GT, Purcell RH. Comparison of tests for antibodies to hepatitis E virus. J Med Virol 1998;58:134–7.

169 Arankalle VA, Tsarev SA, Chada MS, Alling DW, Emerson SU, Strickland et al. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine 2004;22:2578–85.

170 Ghabrah TM, Tsarev S, Yarboough PO, Emerson SU, Strickland GT, Purcell RH. Comparison of tests for antibodies to hepatitis E virus. J Med Virol 1998;58:134–7.

171 Arankalle VA, Tsarev SA, Chada MS, Alling DW, Emerson SU, Strickland et al. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine 2004;22:2578–85.
disease in highly endemic rural Egyptian communities. Trans R Soc Trop Med Hyg 2006;100:89–94.

180 Stoszek SK, Abdel-Hamid M, Saleh DA, El Kafrawy S, Narooz S, Hawash Y, et al. High prevalence of hepatitis E antibodies in pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006;100:95–101.

181 Li RC, Ge SX, Li YP, Zheng YJ, Nong Y, Guo QS, et al. Seroprevalence of hepatitis E virus infection, rural southern People’s Republic of China. Emerg Infect Dis 2006;12:1682–8.

182 Buti M, Dominguez A, Plans P, Jardi R, Schaper M, Espunes J, et al. Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain. Clin Vaccine Immunol 2006;13:1288–32.

183 Olsen B, Axellsson-Olsson D, Thelin A, Weiland O. Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls. Scand J Infect Dis 2006;38:55–8.

184 Thomas DL, Yarbough PO, Vlahov D, Nelson KE, Saah AJ, et al. Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol 1997;35:1244–7.

185 Kikuchi K, Yoshida T, Kimata N, Sato C, Akiba T. Prevalence of hepatitis E virus infection in regular hemodialysis patients. Ther Apher Dial 2006;10:193–7.

186 Cheng PN, Wang RH, Wu IC, Wu JC, Tseng KC, Young KC, et al. Increased hepatitis E virus prevalence on Dutch pig farms from 33 to 55% by using appropriate internal quality controls for RT-PCR. J Virol Methods 2007;143:112–16.

187 Buti M, Chandler JD, Siddell MA, Li F, Love RJ, Anderson DA. Serological evidence for swine hepatitis E virus infection in Australian pig herds. Vet Microbiol 1999;68:95–105.

188 Meng XJ, Dea S, Engle RE, Friendship R, Lyoo YS, Sirinarumitr T, et al. Prevalence of antibodies to the hepatitis E virus in pigs from countries where hepatitis E is common or is rare in the human population. J Med Virol 1999;59:297–302.

189 Nakai I, Kato K, Miyazaki A, Yoshii M, Li TC, Takeda N, et al. Detection of hepatitis E virus (HEV) and postweaning multisystemic wasting syndrome (PMWS) with lesions of hepatitis in pigs. Vet Microbiol 2007;122:16–24.

190 Rutjes SA, Lodder WJ, Bouwknecht M, de Rosda Husman AM. Increased hepatitis E virus prevalence on Dutch pig farms from 33 to 55% by using appropriate internal quality controls for RT-PCR. J Virol Methods 2007;143:112–16.

191 Meng XJ, Dea S, Engle RE, Friendship R, Lyoo YS, Sirinarumitr T, et al. Prevalence of antibodies to the hepatitis E virus in pigs from countries where hepatitis E is common or is rare in the human population. J Med Virol 1999;59:297–302.

192 Takahashi M, Nishizawa T, Tanaka T, Tsatsralt-od B, Inoue J, Okamoto H. Correlation between positivity for immunoglobulin A antibodies and viraemia of swine hepatitis E virus observed among farm pigs in Japan. J Gen Virol 2005;86 (Pt 6): 1807–13.

193 Yoo D, Willson P, Pei Y, Hayes MA, Deckert A, Dewey CE, et al. Prevalence of hepatitis E virus antibodies in Canadian swine herds and identification of a novel variant of swine hepatitis E virus. Clin Diagn Lab Immunol 2001;8:1213–19.

194 BOuwknecht M, Lodder-Verschoor F, van der Poel WH, Rutjes SA, de Rosda Husman AM. Hepatitis E virus RNA in commercial porcine livers in The Netherlands. J Food Prot 2007;70:2889–95.

195 Williams TP, Kasornborkbua C, Halbur PG, Haqshenas G, Guenette DK, Toth TE, Engle RE, et al. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 2002;40:117–22.

196 Tanaka E, Matsumoto A, Takeda N, Li TC, Umemura T, Yoshizawa K, et al. Age-specific antibody to hepatitis E virus has remained constant during the past 20 years in Japan. J Viral Hepat 2005;12:439–42.

197 Meng XJ, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsarev TS, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci USA 1997;94:9860–5.

198 Karednyi YV, Gilchrist MJ, Naides SJ. Hepatitis E virus infection prevalence among selected populations in Iowa. J Clin Microbiol 1999;37:1451–5.

199 Nakai I, Kato K, Miyazaki A, Yoshii M, Li TC, Takeda N, et al. Different fecal shedding patterns of two common strains of hepatitis E virus at three Japanese swine farms. Am J Trop Med Hyg 2006;75:1171–7.

200 Choi C, Chae C. Localization of swine hepatitis E virus in liver and extrahepatic tissues from naturally infected pigs by in situ hybridization. J Hepatol 2003;38:827–32.

201 Kasornborkbua C, Opriessng T, Huang FF, Guenette DK, Thomas PJ, Meng XJ, et al. Infectious swine hepatitis E virus is present in pig manure storage facilities on United States farms, but evidence of water contamination is lacking. Appl Environ Microbiol 2005;71:7831–7.

202 Meng XJ, Halbur PG, Shapiro MS, Govindarajan S, Bruna JD, Mushahwar IK, et al. Genetic and experimental evidence for cross-species infection by swine hepatitis E virus. J Virol 1998;72:9714–21.

203 Meng XJ, Halbur PG, Haynes JS, Tsarev TS, Bruna JD, Royer RL, et al. Experimental infection of pigs with the newly identified swine hepatitis E virus (swine HEV), but not with human strains of HEV. Arch Virol 1998;143:1405–15.

204 Kasornborkbua C, Guenette DK, Huang FF, Thomas PJ, Meng XJ, Halbur PG. Routes of transmission of swine hepatitis E virus in pigs. J Clin Microbiol 2004;42:5047–52.

205 Halbur PG, Kasornborkbua C, Gilbert C, Guenette D, Potters ME, Purcell RH, et al. Comparative pathogenesis of infection of pigs with hepatitis E viruses recovered from a pig and a human. J Clin Microbiol 2001;39:981–93.

206 Martin M, Segales J, Huang FF, Guenette DK, Mateu E, de Deus N, et al. Association of hepatitis E virus (HEV) and postweakening hepatitis E Emerging Health Threats Journal 2008, 1:8
E. Identification of genotype 1 hepatitis E virus in samples from humans in Nepal. J Clin Microbiol 2002;40:4493–8.

He J, Innis BL, Shrestha MP, Clayson ET, Scott RM, Linthicum KJ, et al. Evidence that rodents are a reservoir of hepatitis E virus for humans in Nepal. J Clin Microbiol 2002;40:4493–8.

Starkov SR, Aggarwal R, Jameel S, Pur I, Gupta VK, et al. T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat 2007;14:283–92.

Sal R, Aggarwal R, Naik SR, Das V, Das S, Naik S. Immunological alterations in pregnant women with acute hepatitis E. J Gastroenterol Hepatol 2005;20:1094–101.

Aggarwal R. Hepatitis E and pregnancy. Indian J Gastroenterol 2007;26:3–5.

Srivastava R, Aggarwal R, Jameel S, Pur I, Gupta VK, Ramesh VS, et al. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol 2007;20:56–65.

Tsega E, Krawczynski K, Hansson BG, Nordenfelt E, Negusse Y, Alemu W, et al. Outbreak of acute hepatitis E virus infection among military personnel in northern Ethiopia. J Med Virol 1991;34:232–6.

Krawczynski K, Kamili S, Aggarwal R. Global epidemiology and medical aspects of hepatitis E. Forum (Genova) 2001;11:166–79.

Pearce RH, Emerson SU. Hepatitis E virus in fields Virology. Lippincott, Williams and Wilkins: Philadelphia, 2001.

Nanda SK, Yalcinkaya K, Panighrati AK, Acharya SK, Jameel S, Panda SK. Etiological role of hepatitis E virus in sporadic fulminant hepatitis. J Med Virol 1994;42:133–7.

Arora NK, Nanda SK, Gulati S, Ansari IH, Chawla MK, Gupta SD, et al. Acute viral hepatitis types A, B and C singly and in combination in acute liver failure in children in north India. J Med Virol 1996;48:215–21.

Tsega E, Krawczynski K, Hansson BG, Nordenfelt E. Hepatitis E virus infection in pregnancy in Ethiopia. Ethiop Med J 1993;31:173–81.

Khuroo MS, Tell MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med Sci 1981;270:252–5.

Mirghani OA, Saeed OK, Basama FM. Viral hepatitis in pregnancy. East Afr Med J 1992;69:445–9.

Hussaini SH, Skidmore SJ, Richardson P, Sherratt LM, Cooper BT, O’Grady JG. Severe hepatitis E infection during pregnancy. J Viral Hepat 1997;4:51–4.

Peron JM, Bureau C, Poisson H, Mansuy JM, Alric L, Selve J, et al. Fulminant liver failure from acute acothohnus hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat 2007;14:298–303.

Ohnishi S, Kang JH, Maekubo H, Arakawa T, Karino Y, Toyota J, et al. Comparison of clinical features of acute hepatitis caused by hepatitis E virus (HEV) genotypes 3 and 4 in Sapporo, Japan. J Hepatol Res 2006;36:301–7.

Coursaget P, Buisson Y, N’Gawara MN, Van Cuyck-Gandre H, Coursaget P, Buisson Y, N’Gawara MN, Van Cuyck-Gandre H, Chiyende J, Tan KC, Bradley D, Portmann B, Williams R, et al. Fulminant hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol 2007;20:56–65.

Sallie R, Chiyende J, Tan KC, Bradley D, Portmann B, Williams R, et al. Fulminant hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol 2007;20:56–65.

Nanda SK, Talwar S, Tyagi SK, Arankalle VA, Chadha MS, Tsarev SA, Emerson SU, et al. Seroepidemiology of water-borne hepatitis E virus infection in India and evidence for a third genetically transmitted hepatitis agent. Proc Natl Acad Sci USA 1999;96:3428–32.

Clayson ET, Myint KS, Snitbhan R, Vaughn DW, Innis BL, Clayson ET, Myint KS, Snitbhan R, Vaughn DW, Innis BL, Chan L, et al. Fulminant liver failure from acute acothohnus hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol 2007;20:56–65.

Duffy MR, Shukla R, Jameel S, Agrawal S, Pur I, Gupta VK, et al. T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat 2007;14:283–92.
260 Zamvar V, McClean P, Odeka E, Richards M, Davison S. Hepatitis E virus infection with nonimmune hemolytic anemia. *J Pediatr Gastroenterol Nutr* 2005;40:223–5.

261 Wendum D, Nachury M, Yer M, Lemann M, Flejou JF, Janin A, *et al.* Acute hepatitis E: a cause of lymphocytic destructive cholangitis. *Hum Pathol* 2005;36:436–8.

262 Serratrice J, Disdier P, Colson P, Ene N, de Roux CS, Weiller PJ. Acute polyarthritis revealing hepatitis E. *Clin Rheumatol* 2007;20:1973–5.

263 Worm HC, van der Poel WH, Brandstatter G. Hepatitis E: an overview. *Microbes Infect* 2002;4:657–66.

264 Myint KS, Endy TP, Gibbons RV, Laras K, Mammen Jr MP, Sedyaningsih ER, *et al.* Evaluation of diagnostic assays for hepatitis E virus in outbreak settings. *J Clin Microbiol* 2006;44:1581–3.

265 Mast EE, Alter MJ, Holland PV, Purcell RH. Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. *Hepatology* 1998;27:857–61.

266 Orru G, Masia G, Orru G, Romano L, Piras V, Coppola RC. Detection and quantitation of hepatitis E virus in human faeces by real-time quantitative PCR. *J Virol Methods* 2004;118:77–82.

267 Inoue J, Takahashi M, Yazaki Y, Tsuda F, Okamoto H. Development and validation of an improved RT-PCR assay with nested universal primers for detection of hepatitis E virus strains with significant sequence divergence. *J Virol Methods* 2006;137:325–33.

268 Jothikumar N, Cromeans TL, Robertson BH, Meng XJ, Hill VR. A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. *J Virol Methods* 2006;131:65–71.

269 Wang L, Zhuang H. Hepatitis E: an overview and recent advances in vaccine research. *World J Gastroenterol* 2004;10:2157–2162.

270 Wang HC, Wirnsberger G. Hepatitis E vaccines: progress and prospects. *Drugs* 2004;64:1517–31.

271 Kamili S, Speilbring J, Carson D, Kravczyński K. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection. *J Infect Dis* 2004;189:258–64.